FREDERICK, Md., Jan. 16 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , announced today that it has been selected as a recipient of the Maryland Industrial Partnership (MIPS) award for its’ dental study, “Pulsed Electromagnetic Therapy for Healing.”
The dental study will be conducted by the University of Maryland Dental School. Dr. Sharon Gordon, DDS, MPH, PhD, Associate Professor Biomedical Sciences, Dental School, will be the University’s Principal Investigator. Dr. Richard Cassie, DDS, Clinical Professor of Dentistry, New Jersey School of Dentistry and Medicine, will be the project manager and chief investigator.
“We are proud to have been chosen, by MIPS, to receive this award. The field of competition for this award is large, with an impressive array of scientific, bio-technology and technology candidates. We are also looking forward to working with Dr. Gordon and UMB on the dental study. The results of this study have the potential to generate a great deal of interest in the healing benefits of ActiPatch, not to mention opening up the dental market,” said Andrew Whelan, President of BioElectronics Corporation.
“ActiPatch provides a unique therapy that is non-invasive and drug free. This dental study will provide the evidence based support and confirmation that the use of ActiPatch (PEMF therapy) will produce significant diminution of swelling and pain, and thereby will accelerate healing time. The clinical study will produce the definitive scientific data needed to introduce ActiPatch to the dental practitioners,” said Dr. Cassie.
About Maryland Industrial Partnership Programs:
The Maryland Industrial Partnerships (MIPS) program accelerates the commercialization of technology in Maryland by jointly funding collaborative R&D projects between companies and University System of Maryland faculty. For more information about Maryland Industrial Partnership, please visit: http://www.mips.umd.edu/
BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
http://www.bioelectronicscorp.com
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
CONTACT: Andrew J. Whelan, President & CEO of BioElectronics Corporation,
+1-301-874-4890, fax, +1-301-874-6935, info@bioelectronicscorp.com
Web site: http://www.bioelectronicscorp.com/
http://www.mips.umd.edu//
